Cabotegravir Sodium (1 brand name, 1 dosage form, 1 route)
Available dosage forms: TABLET.
Routes of administration: ORAL.
Brand Names
- VOCABRIA
Related Health Topics
Contraindications
Treatment of HIV-1 Infection VOCABRIA is contraindicated in patients: •with previous hypersensitivity reaction to cabotegravir [see Warnings and Precautions (5.2)]. •receiving the following coadministered drugs for which significant decreases in cabotegravir plasma concentrations may occur due to uridine diphosphate glucuronosyltransferase (UGT)1A1 enzyme induction, which may result in loss of virologic response [see Drug Interactions (7.2, 7.3), Clinical Pharmacology (12.3)]: oAnticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin oAntimycobacterials: Rifampin, rifapentine Prior to initiation of VOCABRIA, note that use of CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) with rifabutin is contraindicated. Since VOCABRIA is taken in combination with EDURANT tablets, the prescribing information for EDURANT should be consulted for additional contraindications. HIV-1 Pre-Exposure Prophylaxis VOCABRIA is contraindicated in individuals: •with unknown or positive HIV-1 status [see Warnings and Precautions (5.1)]. •with previous hypersensitivity reaction to cabotegravir [see Warnings and Precautions (5.2)]. •receiving the following coadministered drugs for which significant decreases in cabotegravir plasma concentrations may occur due to UGT1A1 enzyme induction, which may result in loss of efficacy [see Drug Interactions (7.2, 7.3), Clinical Pharmacology (12.3)]: oAnticonvulsants: Carbamazepine, oxcarbazepine, phenobarbital, phenytoin oAntimycobacterials: Rifampin, rifapentine
Adverse Reactions
The following adverse reactions are described below and in other sections of the labeling: •Hypersensitivity reactions [see Warnings and Precautions (5.2)] •Hepatotoxicity [see Warnings and Precautions (5.3)] •Depressive disorders [see Warnings and Precautions (5.4)]
Mechanism of Action
Cabotegravir is an HIV-1 antiretroviral drug [see Microbiology (12.4)].
Overdosage
There is no known specific treatment for overdose with VOCABRIA. If overdose occurs, monitor the patient and apply standard supportive treatment as required as well as observation of the clinical status of the individual. As cabotegravir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by dialysis.